Research graph
References from Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1093/protein/gzt009
10.1093/protein/gzt009 · External reference
10.18632/oncotarget.24490
10.18632/oncotarget.24490 · External reference
10.4161/mabs.29445
10.4161/mabs.29445 · External reference
10.1158/1078-0432.ccr-18-0455
10.1158/1078-0432.ccr-18-0455 · External reference
10.1126/science.1158545
10.1126/science.1158545 · External reference
10.1007/s00262-010-0844-y
10.1007/s00262-010-0844-y · External reference
10.1080/19420862.2016.1268307
10.1080/19420862.2016.1268307 · External reference
10.1158/1535-7163.mct-15-0647
10.1158/1535-7163.mct-15-0647 · External reference
10.1038/ncomms6479
10.1038/ncomms6479 · External reference
Immunoconjugates containing novel maytansinoids: promising anticancer drugs
1992 · External reference
10.1002/ijc.29007
10.1002/ijc.29007 · External reference
10.1038/nature03843
10.1038/nature03843 · External reference
10.1182/blood-2012-07-442251
10.1182/blood-2012-07-442251 · External reference
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
10.1016/j.abb.2012.03.016 · 2012 · External reference
10.1016/j.tibtech.2010.03.007
10.1016/j.tibtech.2010.03.007 · External reference
Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing
10.1515/hsz-2018-0338 · 2019 · External reference
10.1242/jcs.186205
10.1242/jcs.186205 · External reference
Understanding the structure and function of the immunological synapse
2010 · External reference
10.1016/j.ymeth.2018.10.026
10.1016/j.ymeth.2018.10.026 · External reference
10.1016/s0021-9258(18)47026-3
10.1016/s0021-9258(18)47026-3 · External reference
10.1038/384134a0
10.1038/384134a0 · External reference
Bispecific T-cell engagers for cancer immunotherapy
10.1038/icb.2014.93 · 2015 · External reference
10.1007/s40259-018-0299-9
10.1007/s40259-018-0299-9 · External reference
An anti-EGFR x cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
2018 · External reference
Harnessing MerTK agonism for targeted therapeutics
10.1080/19420862.2019.1685832 · 2020 · External reference
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
10.1038/nm.2942 · 2012 · External reference
10.4161/mabs.4.2.19000
10.4161/mabs.4.2.19000 · External reference
Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses
10.1158/1538-7445.am2018-2719 · 2018 · External reference
10.1038/s41573-019-0028-1
10.1038/s41573-019-0028-1 · External reference
Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment
10.1158/1538-7445.am2016-3217 · 2016 · External reference
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
10.1038/ncomms13354 · 2016 · External reference
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
10.1182/blood-2017-08-801662 · 2017 · External reference
10.1016/j.ccell.2017.02.001
10.1016/j.ccell.2017.02.001 · External reference
A bispecific IgG format containing four independent antigen binding sites
10.1038/s41598-020-58150-z · 2020 · External reference
A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
10.1182/blood.v95.6.2098 · 2000 · External reference
10.1158/1535-7163.mct-17-0657
10.1158/1535-7163.mct-17-0657 · External reference
10.1038/nrd.2018.75
10.1038/nrd.2018.75 · External reference
Dual Agonist surrobody simultaneously activates death receptors DR4 and DR5 to induce cancer cell death
10.1158/1535-7163.mct-15-0400 · 2016 · External reference
10.1016/j.immuni.2006.10.019
10.1016/j.immuni.2006.10.019 · External reference
Tuning T cell affinity improves efficacy and safety of anti-CD38 × anti-CD3 bispecific antibodies in monkeys – a potential therapy for multiple myeloma
10.1182/blood.v126.23.1798.1798 · 2015 · External reference
10.1182/blood-2010-09-306449
10.1182/blood-2010-09-306449 · External reference
10.1016/j.neuron.2013.10.061
10.1016/j.neuron.2013.10.061 · External reference
10.1016/j.molimm.2005.03.007
10.1016/j.molimm.2005.03.007 · External reference
Orchestration of immunological synapse assembly by vesicular trafficking
2019 · External reference
10.1136/esmoopen-2018-000482
10.1136/esmoopen-2018-000482 · External reference
10.1186/s12943-019-1091-2
10.1186/s12943-019-1091-2 · External reference
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
10.4161/mabs.28591 · 2014 · External reference
Understanding the spatial topology of artificial immunological synapses assembled in T cell-redirecting strategies: a major issue in cancer immunotherapy
2020 · External reference
Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer
2016 · External reference
10.1126/scitranslmed.aax1315
10.1126/scitranslmed.aax1315 · External reference
Bispecific antibodies: design, therapy, perspectives
10.2147/dddt.s151282 · 2018 · External reference
10.1074/jbc.ra118.001752
10.1074/jbc.ra118.001752 · External reference
10.1016/j.molimm.2015.01.003
10.1016/j.molimm.2015.01.003 · External reference
10.1038/314628a0
10.1038/314628a0 · External reference
10.3390/antib8030041
10.3390/antib8030041 · External reference
The analysis of key factors related to ADCs structural design
2019 · External reference
10.1002/(sici)1097-0215(19960516)66:4<477::aid-ijc11>3.0.co;2-5
10.1002/(sici)1097-0215(19960516)66:4<477::aid-ijc11>3.0.co;2-5 · External reference
10.1200/jco.2014.56.3247
10.1200/jco.2014.56.3247 · External reference
10.3389/fimmu.2015.00368
10.3389/fimmu.2015.00368 · External reference
10.1016/j.celrep.2017.12.019
10.1016/j.celrep.2017.12.019 · External reference
10.1158/0008-5472.can-11-1620
10.1158/0008-5472.can-11-1620 · External reference
10.3390/antib4040426
10.3390/antib4040426 · External reference
10.1080/19420862.2019.1625662
10.1080/19420862.2019.1625662 · External reference
10.1016/j.csbj.2020.05.007 · Admitted local publication
